Activation of the Coagulant Pathway in Cigarette Smokers

G. J. Miller; K. A. Bauer; J. A. Cooper; R. D. Rosenberg

doi:10.1055/s-0037-1614942

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 79(03): 549-553
DOI: 10.1055/s-0037-1614942

Review Articles

Schattauer GmbH

Activation of the Coagulant Pathway in Cigarette Smokers

Authors

G. J. Miller

¹Medical Research Council Epidemiology and Medical Care Unit, London, England
K. A. Bauer

²Molecular Medicine Unit, Beth Israel Hospital, Boston, MA, USA
J. A. Cooper

¹Medical Research Council Epidemiology and Medical Care Unit, London, England
R. D. Rosenberg

²Molecular Medicine Unit, Beth Israel Hospital, Boston, MA, USA

Abstract

Summary

The effects of chronic cigarette smoking on the coagulation system were examined in 2964 men aged 50 to 61 years and clinically free of cardiovascular disease. Factor VII activity (VIIc), factor VII antigen (VIIag), prothrombin fragment 1+2 (F_1.2), fibrinopeptide A (FPA) and fibrinogen were measured in all participants, and activated factor VII (VIIa), factor IX activation peptide (IX pep) and factor X activation peptide (X pep) in a large sub-sample. The levels of all indices except FPA differed significantly between non-smokers, ex-smokers and current smokers. After adjustment for other conventional cardiovascular risk factors, mean VIIc was raised slightly by 3% in ex-smokers and current smokers as compared with non-smokers, owing to increases in VIIa and VIIag. Plasma IX pep, X pep, F_1.2 and fibrinogen concentration were highest in current smokers, intermediate in ex-smokers and lowest in non-smokers. These findings accord with the increased risk of arterial thrombosis in smokers.

Full Text

References

References
1 Doll R, Peto R. Mortality in relation to smoking: 20 years‘ observations on male British doctors. Br Med J 1976; 2: 1525-36.
2 Mann JI, Doll R, Thorogood M, Vessey MP, Waters WE. Risk factors for myocardial infarction in young women. Br J Prev Soc Med 1976; 30: 94-100.
3 US Dept of Health and Human Services.. Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General. DHHS publication no 88-8406. Washington, DC.: US Government Printing Office; 1989
4 Bonita R, Scragg R, Stewart A, Jackson R, Beaglehole R. Cigarette smoking and risk of premature stroke in men and women. Br Med J 1986; 293: 6-8.
5 Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 1985; 33: 13-8.
6 Fowkes FGR, Housley E, Riemersma RA, MacIntyre CCA, Cawood EHH, Prescott RX, Ruckley CV. Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared to ischaemic heart disease: Edinburgh Artery Study. Am J Epidemiol 1992; 135: 331-40.
7 Murphy EA, Mustard JF. Tobacco and thrombosis. Am J Public Health 1966; 56: 1061-73.
8 Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Br Med J 1989; 298: 784-8.
9 Kallner A, Hartmann D, Hornig D. On the requirements of ascorbic acid in man: steady-state turnover and body pool in smokers. Am J Clin Nutr 1981; 34: 1347-55.
10 Pittilo BM. Cigarette smoking and endothelial injury: a review. In: Tobacco smoking and atherosclerosis. Diana JN. (ed) New York: Plenum Press; 1990. pp 61-78.
11 Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemo-dynamic and metabolic events. N Engl J Med 1976; 295: 573-7.
12 Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J 1994; 128: 7-11.
13 Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; ii: 986-8.
14 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
15 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
16 Fischer S, Bernutz C, Meier H, Weber PC. Formation of prostacyclin and thromboxane in men as measured by the main urinary metabolites. Biochim Biophys Acta 1986; 876: 194-9.
17 Murray JJ, Nowak J, Oates JA, FitzGerald GA. Biosynthesis of thromboxane A₂ and prostacyclin during chronic cigarette smoking and withdrawal in men. Clin Res 1985; 33: 521A.
18 Benowitz NL, FitzGerald GA, Wilson M, Zhang QI. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol 1993; 22: 1159-67.
19 Conlon MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sorlie P, Wu KK. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemost 1994; 72: 551-6.
20 Conlon MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 762-7.
21 Conlon MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 380-5.
22 Blann AD, McCollum CN. Adverse influence of cigarette smoking on the endothelium. Thromb Haemost 1993; 70: 707-11.
23 Cushman M, Psaty BM, Macy E, Bovill EG, Cornell ES, Kuller LH, Tracy RP. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol 1996; 16: 1163-9.
24 Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993; 117: 71-7.
25 Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem 1993; 39: 683-6.
26 Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996; 75: 767-71.
27 Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull WHO 1962; 27: 645-58.
28 Medical Research Council’s Committee on Research on Chronic Bronchitis.. Questionnaire on Respiratory Symptoms. Publications Group, Medical Research Council, 20 Park Crescent, London, W1N 4AL, UK.
29 Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD. The effects of the quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost 1995; 73: 82-6.
30 Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994; 71: 38-48.
31 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
32 von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
33 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F₂/F₁₊₂ fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-97.
34 Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
35 Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007-15.
36 Snedecor GW, Cochran WG. Statistical Methods. Iowa State University Press; Ames, Iowa: 1980. pp 291-2.
37 Scheffé H. The Analysis of Variance. Wiley; New York: 1959
38 Meade TW, North WRA, Chakrabarti R, Haines AP, Stirling Y. Population-based distributions of haemostatic variables. Br Med Bull 1977; 33: 283-8.
39 Yarnell JWG, Fehily AM, Milbank J, Kubicki AJ, Eastham R, Hayes TM. Determinants of plasma lipoproteins and coagulation factors in men from Caerphilly, South Wales. J Epidemiol Commun Health 1983; 37: 137-40.
40 Gris J-C, Schved J-F, Feugeas O, Aguilar-Martinez P, Arnaud A, Sanchez N, Sarlat C. Impact of smoking, physical training and weight reduction on FVII, PAI-1, and hemostatic factors in sedentary men. Thromb Haemost 1990; 64: 516-20.
41 Balleisen L, Bailey J, Epping P-H, Schulte H, van de Loo J. Epidemiological study on factor VII, Factor VIII and fibrinogen in an industrial population. 1. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-9.
42 Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, Tracy RP. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly. Am J Epidemiol 1996; 143: 665-76.
43 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
44 Cigolini M, Targher G, Seidell JC, Schiavon R, Tonoli M, Muggeo M, de Sandre G. Plasma factor VII and its relation to adipose tissue fatty acids and other atherogenic risk factors in healthy men. Europ J Clin Invest 1996; 26: 247-53.
45 Hemker HC, Muller AD, Gonggrijp R. The estimation of activated human blood coagulation factor VII. J Mol Med 1976; 1: 127-34.
46 Green D, Ruth KJ, Folsom AR, Liu K. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb 1994; 14: 686-93.
47 Belch JJF, McArdle BM, Burns P, Lowe GDO, Forbes CD. The effects of acute smoking on platelet behaviour, fibrinolysis and haemorheology in habitual smokers. Thromb Haemost 1984; 51: 6-8.
48 Radcliffe R, Bagdasarian A, Colman RW, Nemerson Y. Activation of bovine Factor VII by Hageman factor fragments. Blood 1977; 50: 611-17.
49 Seligsohn U, Østerud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems. Roles of activated factor IX, kallikrein and activated factor XII. J Clin Invest 1979; 64: 1056-65.
50 Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-6.
51 Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990; 7: 147-59.
52 Qureshi GD, Guzelian PS, Vennart RM, Evans HJ. Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen fragment E. Biochim Biophys Acta 1985; 844: 288-95.